Zymeworks (NASDAQ:ZYME – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05), FiscalAI reports. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%.The company had revenue of $4.59 million for the quarter, compared to the consensus estimate of $3.81 million. During the same period last year, the firm earned $0.03 earnings per share. The company’s revenue for the quarter was down 90.6% compared to the same quarter last year.
Zymeworks Trading Up 1.8%
NASDAQ ZYME traded up $0.41 during midday trading on Friday, hitting $23.54. The company had a trading volume of 578,107 shares, compared to its average volume of 672,596. The company has a market capitalization of $1.72 billion, a PE ratio of -17.18 and a beta of 1.15. The firm has a 50-day moving average price of $24.02 and a 200-day moving average price of $24.46. Zymeworks has a twelve month low of $11.51 and a twelve month high of $29.75.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. Stifel Nicolaus set a $46.00 target price on Zymeworks in a research note on Friday. HC Wainwright lifted their price target on Zymeworks from $46.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup restated a “buy” rating on shares of Zymeworks in a research note on Tuesday, June 30th. Finally, Wells Fargo & Company upped their price objective on Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.22.
Key Zymeworks News
Here are the key news stories impacting Zymeworks this week:
- Positive Sentiment: Truist raises target and maintains a Buy rating: Truist Financial lifted its price target from $31 to $32, implying substantial upside from recent trading levels. The firm’s continued Buy recommendation may support investor confidence. Benzinga article
- Positive Sentiment: Analysts remain broadly bullish: HC Wainwright reiterated its Buy rating and $51 price target, while a separate brokerage report cited an average price target of $37.33. These targets suggest analysts see meaningful long-term value in Zymeworks despite near-term losses. Average price target article
- Neutral Sentiment: Revenue exceeded expectations: Zymeworks reported quarterly revenue of $4.59 million, ahead of the $3.81 million consensus estimate. However, the company remains unprofitable, limiting the positive impact of the revenue beat. Zacks earnings article
- Negative Sentiment: Quarterly loss was wider than expected: Zymeworks posted a loss of $0.62 per share, missing estimates for a $0.56–$0.57 loss and reversing year-earlier earnings of $0.03 per share. Revenue also declined 90.6% year over year, while the company reported a negative net margin and return on equity. Zymeworks earnings release
- Negative Sentiment: HC Wainwright cut earnings forecasts: The firm reduced its FY2026 EPS estimate from $1.00 to $0.36 and lowered its Q2 and Q4 forecasts to losses of $0.58 and $0.54 per share, respectively. It also trimmed its Q3 estimate to $2.09 from $2.17, signaling weaker near-term earnings expectations.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Quarry LP bought a new position in Zymeworks in the 3rd quarter valued at about $50,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Zymeworks during the 4th quarter worth approximately $55,000. Tower Research Capital LLC TRC boosted its position in shares of Zymeworks by 29.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock worth $62,000 after acquiring an additional 1,131 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Zymeworks by 157.7% in the second quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company’s stock valued at $129,000 after acquiring an additional 6,307 shares during the last quarter. Finally, Brevan Howard Capital Management LP acquired a new position in Zymeworks during the second quarter valued at approximately $133,000. Institutional investors and hedge funds own 92.89% of the company’s stock.
Zymeworks announced that its Board of Directors has initiated a share buyback program on Thursday, May 14th that authorizes the company to buyback $125.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 7% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.
At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.
Read More
- Five stocks we like better than Zymeworks
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
